Sarepta Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene ther...
Latest News
7 days ago · marketbeat.com
Sarepta Therapeutics Sees Transformational 2027 as Rare Disease Programs AdvanceSarepta Therapeutics NASDAQ: SRPT expects updates from its experimental neuromuscular disease programs to help shape its next phase of growth, while relying on its Duchenne muscular dystrophy business to fund development, CEO Michael Severino said at Guggenheim's Third Healthcare Innovation conference.
9 days ago · seekingalpha.com
Sarepta Therapeutics, Inc. (SRPT) Q3 2026 Earnings Call TranscriptSarepta Therapeutics, Inc. ( SRPT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO & Director Patrick Moss - Executive VP & Chief Commercial Officer Louise Rodino-Klapac - President of Research & Development and Technical Operations Ryan Wong - Executive VP & CFO James Richardson - Executive VP & Chief Medical Officer Conference Call Participants Adhiraj Chauhan - JPMorgan Chase & Co, Research Division Konstantinos Biliouris - Oppenheimer & Co. Inc., Research Division Brian Abrahams - RBC Capital Markets, Research Division Lin Tsai - Jefferies LLC, Research Division Eliana Merle - Barclays Bank PLC, Research Division Joshua Fleishman - TD Cowen, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division David Hoang - Deutsche Bank AG, Research Division Tommie Reerink - Goldman Sachs Group, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.
11 days ago · zacks.com
SRPT Q3 Earnings Miss Estimates, Stock Down as Elevidys Sales DeclineSarepta's mixed Q3 results send shares down, as earnings miss and weaker Elevidys sales weigh on investor sentiment.
11 days ago · marketbeat.com
Sarepta Therapeutics Q3 Earnings Call HighlightsSarepta Therapeutics NASDAQ: SRPT raised the low end of its 2026 product revenue forecast after reporting stable demand indicators for Duchenne muscular dystrophy gene therapy ELEVIDYS and continued strength in its exon-skipping drug franchise.
11 days ago · zacks.com
Compared to Estimates, Sarepta Therapeutics (SRPT) Q3 Earnings: A Look at Key MetricsWhile the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
19 days ago · zacks.com
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
21 days ago · businesswire.com
Sarepta Therapeutics to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim Securities 3rd Annual Healthcare Innovation Conference in BostonFireside chat: 3 p.m. ETThe presentation from the Guggenheim conference will be webcast live under the in.
26 days ago · businesswire.com
Sarepta Therapeutics to Announce Third Quarter 2026 Financial ResultsCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026. Subsequently, at 4:30 p.m. ET, the Company will host a conference call to discuss these results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations.
1 month ago · businesswire.com
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual MeetingCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) demonstrating that SRP-1003, the company's investigational small interfering RNA (siRNA) program for the treatment of myotonic dystrophy type 1 (DM1), can directly reduce pathogenic DMPK transcripts within the nucleus, where the molecular drivers o.
1 month ago · benzinga.com
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'On CNBC's “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove SRPT